Benitec Biopharma (NASDAQ:BNTC - Get Free Report) issued its quarterly earnings results on Friday. The biotechnology company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.19, Zacks reports.
Benitec Biopharma Stock Performance
Shares of NASDAQ BNTC traded up $0.01 during trading hours on Tuesday, hitting $11.26. The company's stock had a trading volume of 20,097 shares, compared to its average volume of 31,603. Benitec Biopharma has a 12 month low of $2.75 and a 12 month high of $13.29. The stock has a market cap of $261.46 million, a price-to-earnings ratio of -2.84 and a beta of 0.81. The business has a 50-day simple moving average of $11.35 and a 200-day simple moving average of $10.29.
Insider Buying and Selling at Benitec Biopharma
In related news, Director Suvretta Capital Management, L acquired 27,502 shares of Benitec Biopharma stock in a transaction on Monday, December 23rd. The shares were acquired at an average cost of $10.98 per share, with a total value of $301,971.96. Following the transaction, the director now owns 7,981,725 shares in the company, valued at $87,639,340.50. This trade represents a 0.35 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
Several research firms recently commented on BNTC. Guggenheim reaffirmed a "buy" rating and set a $17.00 target price on shares of Benitec Biopharma in a report on Tuesday, December 3rd. HC Wainwright started coverage on Benitec Biopharma in a research note on Monday, December 16th. They set a "buy" rating and a $28.00 price objective on the stock. Robert W. Baird started coverage on Benitec Biopharma in a report on Friday, December 13th. They issued an "outperform" rating and a $30.00 price objective on the stock. Finally, Baird R W upgraded Benitec Biopharma to a "strong-buy" rating in a report on Thursday, December 12th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Benitec Biopharma has an average rating of "Buy" and an average price target of $24.43.
Read Our Latest Stock Report on BNTC
About Benitec Biopharma
(
Get Free Report)
Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Recommended Stories
Before you consider Benitec Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.
While Benitec Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
